Understanding the uptake of respiratory syncytial virus prevention products by pregnant people and newborns in order to improve public health policy

REspiratory Syncytial VIrus VaccinE and Nirsevimab Uptake in Pregnancy and Neonates: the “REVIVE” study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12625001272482

Acronym

REVIVE

Enrollment

10000

Registered

2025-11-14

Start date

2025-11-17

Completion date

2026-09-30

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The REVIVE Study aims to understand the uptake of RSV prevention products recently introduced to protect newborns from RSV disease. It will assess the uptake of the maternal RSV vaccine amongst pregnant people birthing at Monash Health during 2025-2026. The uptake of RSV monoclonal antibody amongst eligible infants will also be assessed. The study will also evaluate the demographic factors associated with the uptake of these products. Overall, the REVIVE Study will paint a picture of our newborns' current level of protection against RSV and help us understand how to better direct public health messaging in order to maximise the uptake of vaccination programs.

Interventions

This study observes pregnant people and their babies born at Monash Health from July 1st 2025. Data will be collected from participants' medical records at one point in time, 2 weeks after the birth of the baby in order to assess the uptake of RSV prevention products. Participants do not undergo any procedures as part of this study.

Eligibility

Sex/Gender

All

Healthy volunteers

Inclusion criteria

Pregnant people birthing at Monash Health Aged 18 years and over Medicare card holder All live newborns born at Monash Health

Exclusion criteria

Not birthing at Monash Health Less than 18 years of age Non- Medicare card holder Stillbirth

Outcome results